Conversely, SLC44A2 was significantly upregulated in glioblastoma multiforme (GBM), lower-grade glioma (LGG), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), invasive breast carcinoma (BRCA), gastric and esophageal carcinoma (STES), gastric adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UCEC), liver hepatocellular carcinoma (LIHC), thyroid carcinoma (THCA), pheochromocytoma and paraganglioma (PCPG), bladder urothelial carcinoma (BLCA), and cholangiocarcinoma (CHOL) (Fig. S1B). Here, SLC44A2 is linked to thyroid gland carcinoma.